AstraZeneca Installs Genentech's Bohen To Head Late Development
This article was originally published in Scrip
Executive Summary
Immersed in a wide-ranging R&D overhaul, AstraZeneca PLC has moved quickly to fill a key gap in its senior management team by appointing Sean Bohen its new executive vice president of global medicines development and chief medical officer, replacing Briggs Morrison who vacated the post in June to join a biotech.